论文部分内容阅读
目的:观察帕罗西汀治疗非便秘型肠易激综合征的临床疗效。方法:符合罗马Ⅲ诊断标准的非便秘型肠易激综合征患者107例,随机分为2组,治疗组57例,给予帕罗西汀20 mg,每日晨起顿服,匹维溴铵50 mg,3次/d,口服;对照组50例,给予谷维素30 mg,3次/d,口服,匹维溴铵50 mg,3次/d,口服,疗程4周。观察患者腹痛、腹泻、腹部不适、排便次数、大便性状,以及焦虑、抑郁等改善情况。结果:治疗组总有效率为93.0%,对照组总有效率为76.0%,两组比较差异有统计学意义(P<0.01)。结论:帕罗西汀治疗非便秘型肠易激综合征有明确的临床意义。
Objective: To observe the clinical efficacy of paroxetine in the treatment of non-constipated irritable bowel syndrome. Methods: A total of 107 patients with non-constipation-predominant irritable bowel syndrome who meet the diagnostic criteria of Rome Ⅲ were randomly divided into two groups. The treatment group was given 57 mg paroxetine 20 mg daily, , 3 times / d, orally; control group of 50 cases, given oryzanol 30 mg, 3 times / d, orally, pinaverium bromide 50 mg, 3 times / d, oral treatment for 4 weeks. Observe abdominal pain, diarrhea, abdominal discomfort, defecation frequency, stool, as well as anxiety, depression and other improvements. Results: The total effective rate was 93.0% in the treatment group and 76.0% in the control group. The difference between the two groups was statistically significant (P <0.01). Conclusion: Paroxetine has a clear clinical significance in the treatment of non-constipated irritable bowel syndrome.